Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 685-695

  Wang, Huiming ^a   Zhang, Liang ^a   Kung, Sam Kp ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

dendritic cell; gene delivery; immune regulation; immunotherapy; lentiviral vector

Indexed keywords

LENTIVIRUS VECTOR; SHORT HAIRPIN RNA;

ALLERGY; ANTIGEN RECOGNITION; AUTOIMMUNITY; DENDRITIC CELL BASED IMMUNOTHERAPY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; NEOPLASM; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LENTIVIRUS INFECTIONS;

EID: 77957594057     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.44     Document Type: Review

References (123)

1. O'Sullivan B, Thomas R: CD40 and dendritic cell function. Crit. Rev. Immunol. 23(1-2), 83-107 (2003).
2. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002).
3. Kalinski P, Moser M: Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5(3), 251-260 (2005).
4. Reis ESC: Dendritic cells in a mature age. Nat. Rev. Immunol. 6(6), 476-483 (2006).
5. + CD38-human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl Acad. Sci. USA 96(6), 2988-2993 (1999).
6. Roe T, Reynolds TC, Yu G et al.: Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12(5), 2099-2108 (1993).
7. Kafri T, Blomer U, Peterson DA et al.: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17(3), 314-317 (1997).
8. Kim VN, Mitrophanous K, Kingsman SM et al.: Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72(1), 811-816 (1998).
9. Zufferey R, Nagy D, Mandel RJ et al.: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15(9), 871-875 (1997).
10. Mochizuki H, Schwartz JP, Tanaka K et al.: High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72(11), 8873-8883 (1998).
11. Naldini L, Blomer U, Gage FH et al.: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93(21), 11382-11388 (1996).
12. Naldini L, Blomer U, Gallay P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996).
13. Miyoshi H, Blomer U, Takahashi M et al.: Development of a self-inactivating lentivirus vector. J. Virol. 72(10), 8150-8157 (1998).
14. Zufferey R, Dull T, Mandel RJ et al.: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12), 9873-9880 (1998).
15. + progenitor cells. Mol. Ther. 8(6), 981-991 (2003).
16. Tuyaerts S, Noppe SM, Corthals J et al.: Generation of large numbers of dendritic cells in a closed system using cell factories. J. Immunol. Methods 264(1-2), 135-151 (2002).
17. Kutner RH, Zhang XY, Reiser J: Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 4(4), 495-505 (2009).
18. Ansorge S, Lanthier S, Transfiguracion J et al.: Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med. 11(10), 868-876 (2009).
19. Zhang L, Procuik M, Fang T et al.: Functional analysis of the quantitative expression of a costimulatory molecule on dendritic cells using lentiviral vector-mediated RNA interference. J. Immunol. Methods 344(2), 87-97 (2009). □ Established a platform that utilized of shRNA of different gene silencing potencies in controlling the expression of CD40 on the modified dendritic cells (DCs). Quantitative expression of CD40 on the lipopolysaccharide (LPS)-activated DC demonstrated different functional abilities in vitro.
20. Veron P, Boutin S, Martin S et al.: Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation. J. Transl. Med. 7, 10 (2009).
21. Breckpot K, Emeagi PU, Thielemans K: Lentiviral vectors for antitumor immunotherapy. Curr. Gene Ther.. 8(6), 438-448 (2008).
22. He Y, Zhang J, Mi Z et al.: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J. Immunol. 174(6), 3808-3817 (2005).
23. Metharom P, Ellem KA, Wei MQ: Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell. Mol. Immunol. 2(4), 281-288 (2005).
24. Breckpot K, Heirman C, De Greef C et al.: Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol. 172(4), 2232-2237 (2004).
25. Lopes L, Fletcher K, Ikeda Y et al.: Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother. 55(8), 1011-1016 (2006).
26. Metharom P, Ellem KA, Schmidt C et al.: Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 12(18), 2203-2213 (2001).
27. Dullaers M, Van Meirvenne S, Heirman C et al.: Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13(7), 630-640 (2006).
28. Akazawa T, Shingai M, Sasai M et al.: Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. Febs Lett. 581(18), 3334-3340 (2007).
29. Song XT, Evel-Kabler K, Shen L et al.: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cellmediated suppression. Nat. Med. 14(3), 258-265 (2008).
30. Wang T, Jiang Q, Chan C et al.: Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. Blood 113(13), 2906-2913 (2009).
31. Koya RC, Kasahara N, Favaro PM et al.: Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J. Immunother. 26(5), 451-460 (2003).
32. + T-cell response in vitro. Int. J. Hematol. 79(4), 377-383 (2004).
33. Zhang X, Zhao P, Kennedy C et al.: Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther. 15(2), 73-84 (2008).
34. Han S, Wang B, Cotter MJ et al.: Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol. Ther. 16(2), 269-279 (2008).
35. Wang B, Han S, Lien L et al.: Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype. Immunology 128(1), 43-57 (2009).
36. Zarei S, Abraham S, Arrighi JF et al.: Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J. Virol. 78(14), 7843-7845 (2004).
37. + T cell responses. Vaccine 28(4), 922-933 (2010).
38. Toscano MG, Delgado M, Kong W et al.: Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol. Ther. 18(5), 1035-1045 (2010).
39. Zhang Y, Yang H, Xiao B et al.: Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis. Mol. Immunol. 46(4), 657-667 (2009).
40. Henry E, Desmet CJ, Garze V et al.: Dendritic cells genetically engineered to express IL-10 induce long-lasting antigenspecific tolerance in experimental asthma. J. Immunol. 181(10), 7230-7242 (2008).
41. Besche V, Wiechmann N, Castor T et al.: Dendritic cells lentivirally engineered to overexpress interleukin-10 inhibit contact hypersensitivity responses, despite their partial activation induced by transductionassociated physical stress. J. Gene Med. 12(3), 231-243 (2010).
42. Breckpot K, Aerts JL, Thielemans K: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14(11), 847-862 (2007).
43. + T cell responses. J. Clin. Invest. 111(11), 1673-1681 (2003). □ Reports the seminal finding that direct subcutaneous injection of lentiviral vectors supported transduction of skin DCs and induction of T-cell responses in vivo.
44. Palmowski MJ, Lopes L, Ikeda Y et al.: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 172(3), 1582-1587 (2004).
45. Rowe HM, Lopes L, Ikeda Y et al.: Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 13(2), 310-319 (2006).
46. Iglesias MC, Frenkiel MP, Mollier K et al.: A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J. Gene Med. 8(3), 265-274 (2006).
47. Kim JH, Majumder N, Lin H et al.: Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther. 16(11), 1255-1266 (2005).
48. He Y, Zhang J, Donahue C et al.: Skinderived dendritic cells induce potent CD8+ T cell immunity in recombinant lentivectormediated genetic immunization. Immunity 24(5), 643-656 (2006).
49. + memory T cells by recombinant lentivectors. Cancer Res. 66(2), 1155-1160 (2006).
50. Vanden Driessche T, Thorrez L, Naldini L et al.: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100(3), 813-822 (2002).
51. Arce F, Rowe HM, Chain B et al.: Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol. Ther. 17(9), 1643-1650 (2009).
52. He Y, Falo LD: Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector. Immunol. Res. 36(1-3), 101-117 (2006). □ This paper, together with [81], characterizes the induction of antigen-specific immunity induced by the lentiviral vectors administrated via different routes of injection.
53. + T cell priming following immunization with lentivectors. J. Immunol. 184(9), 4889-4897 (2010).
54. Iglesias MC, Mollier K, Beignon AS et al.: Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol. Ther. 15(6), 1203-1210 (2007).
55. Beignon AS, Mollier K, Liard C et al.: Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J. Virol. 83(21), 10963-10974 (2009).
56. Kalinski P, Wieckowski E, Muthuswamy R et al.: Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. Methods Mol. Biol. 595, 117-133 (2010). □ This paper, together with [59], highlights the potential of using DCs to differentiate specific T-cell subsets in vitro.
57. Zhang ZX, Yang L, Young KJ et al.: Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 6(7), 782-789 (2000).
58. Thomson CW, Teft WA, Chen W et al.: FcR γ presence in TCR complex of double-negative T cells is critical for their regulatory function. J. Immunol. 177(4), 2250-2257 (2006).
59. Thomson CW, Mossoba ME, Siatskas C et al.: Lentivirally transduced recipientderived dendritic cells serve to ex vivo expand functional FcRγ-sufficient double-negative regulatory T cells. Mol. Ther. 15(4), 818-824 (2007). □ This paper, together with [56], highlights the potential of using DCs to differentiate specific T-cell subsets in vitro.
60. Felice B, Cattoglio C, Cittaro D et al.: Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One 4(2), E4571 (2009).
61. Apolonia L, Waddington SN, Fernandes C et al.: Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol. Ther. 15(11), 1947-1954 (2007).
62. Negri DR, Michelini Z, Baroncelli S et al.: Successful immunization with a single injection of non-integrating lentiviral vector. Mol. Ther. 15(9), 1716-1723 (2007).
63. Rahim AA, Wong AM, Howe SJ et al.: Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther. 16(4), 509-520 (2009).
64. + T cells. Hum. Gene Ther. 21(8), 1029-1035 (2010). □ Describes the use of a nonintegrating lentiviral vector in the transduction of human DCs, and in the expansion of antigen-specific human T cells in vitro.
65. Coutant F, Frenkiel MP, Despres P et al.: Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3(12), e3973 (2008).
66. Cui Y, Golob J, Kelleher E et al.: Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99(2), 399-408 (2002).
67. Dresch C, Edelmann SL, Marconi P et al.: Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J. Immunol. 181(7), 4495-4506 (2008).
68. Zhang J, Zou L, Liu Q et al.: Rapid generation of dendritic cell specific transgenic mice by lentiviral vectors. Transgenic Res. 18(6), 921-931 (2009).
69. Morizono K, Xie Y, Helguera G et al.: A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J. Gene Med. 11(8), 655-663 (2009).
70. Morizono K, Pariente N, Xie Y et al.: Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J. Gene Med. 11(7), 549-558 (2009).
71. Morizono K, Xie Y, Ringpis GE et al.: Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11(3), 346-352 (2005). □ Described the use of a novel genetically engineered Sindbis glycoprotein for tumor-specific targeting in immunodeficient mice in vivo.
72. Dai B, Yang L, Yang H et al.: HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc. Natl Acad. Sci. USA, 106(48), 20382-20387 (2009).
73. Yang L, Yang H, Rideout K et al.: Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26(3), 326-334 (2008). □ This paper, together with [74], describes the use of genetically engineered Sindbis glycoprotein for DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (SIGN)-specific DC cell targeting.
74. Morizono K, Ku A, Xie Y et al.: Redirecting lentiviral vectors by modification of N-linked glycans of envelope proteins. J. Virol. 84(14), 6923-6934 (2010). □ This paper, together with [73], describes the use of genetically engineered Sindbis glycoprotein for DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (SIGN)-specific DC cell targeting.
75. Kung SK, An DS, Chen IS: A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes. J. Virol. 74(8), 3668-3681 (2000).
76. Kung SK, Bonifacino A, Metzger ME et al.: Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum. Gene Ther. 16(4), 527-532 (2005).
77. Tran J, Kung SK: Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells. Mol. Ther. 15(7), 1331-1339 (2007).
78. Carissimi C, Fulci V, Macino G: MicroRNAs: novel regulators of immunity. Autoimmun. Rev. 8(6), 520-524 (2009).
79. O'Connell RM, Rao DS, Chaudhuri AA et al.: Physiological and pathological roles for microRNAs in the immune system. Nat. Rev Immunol. 10(2), 111-122 (2010).
80. Gentner B, Schira G, Giustacchini A et al.: Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 6(1), 63-66 (2009).
81. Brown BD, Gentner B, Cantore A et al.: Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25(12), 1457-1467 (2007). □ This paper, together with [52, 83], characterizes the induction of antigen-specific immunity induced by the lentiviral vectors administrated via different routes of injection.
82. Brown BD, Venneri MA, Zingale A et al.: Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12(5), 585-591 (2006).
83. Annoni A, Brown BD, Cantore A et al.: In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 114(25), 5152-5161 (2009). □ This paper, together with [81], describes the incorporation of specific miRNA target sequences in regulating transgene expression in a cell type of interest in vivo. It also demonstrated expression of antigen in nonantigen-presenting cell-induced regulatory T cells and immunologic tolerance in vivo.
84. Bontkes HJ, Kramer D, Ruizendaal JJ et al.: Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin. Immunol. 127(3), 375-384 (2008).
85. Fukushima S, Hirata S, Motomura Y et al.: Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J. Immunother. 32(3), 219-231 (2009).
86. Brown BD, Sitia G, Annoni A et al.: In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 109(7), 2797-2805 (2007).
87. Pichlmair A, Diebold SS, Gschmeissner S et al.: Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J. Virol. 81(2), 539-547 (2007).
88. Chen X, He J, Chang LJ: Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 1(1), 37 (2004).
89. Gruber A, Kan-Mitchell J, Kuhen KL et al.: Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96(4), 1327-1333 (2000).
90. Breckpot K, Escors D, Arce F et al.: HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol. 84(11), 5627-5636 (2010). □ Demonstrates activation of mouse DCs by lentiviral vectors to be dependent on cell entry and reverse transcription. Moreover, such activation is dependent on Toll-like receptor (TLR) 3 and TLR7-mediated TLR signaling.
91. Pecher G, Haring A, Kaiser L et al.: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. 51(11-12), 669-673 (2002).
92. Pecher G, Spahn G, Schirrmann T et al.: Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anti Cancer Res. 21 (4 A), 2591-2596 (2001).
93. Kyte JA, Kvalheim G, Lislerud K et al.: T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 56(5), 659-675 (2007).
94. Tsao H, Millman P, Linette GP et al.: Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch. Dermatol. 138(6), 799-802 (2002).
95. Mossoba ME, Walia JS, Rasaiah VI et al.: Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol. Ther. 16(3), 607-617 (2008).
96. Abdel-Wahab Z, Kalady MF, Emani S et al.: Induction of antimelanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cell Immunol. 224(2), 86-97 (2003).
97. Zhang L, Tang Y, Akbulut H et al.: An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc. Natl Acad. Sci. USA 100(25), 15101-15106 (2003).
98. Yanagita S, Hori T, Matsubara Y et al.: Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity. Br. J. Haematol. 124(4), 454-462 (2004).
99. Yurkovetsky ZR, Shurin GV, Barry DA et al.: Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J. Gene Med. 8(2), 129-137 (2006).
100. Tsang KY, Zhu M, Even J et al.: The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res. 61(20), 7568-7576 (2001).
101. + T-cell immunity by immature dendritic cells in a vaccination setting. Blood 113(21), 5167-5175 (2009).
102. Yang S, Tsang KY, Schlom J: Induction of higher-avidity human CTLs by vectormediated enhanced costimulation of antigen-presenting cells. Clin. Cancer Res. 11(15), 5603-5615 (2005).
103. Strobel I, Berchtold S, Gotze A et al.: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7(23), 2028-2035 (2000).
104. Yu Y, Pilgrim P, Yan J et al.: Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J. Transl. Med. 6, 56 (2008).
105. Hosoya N, Miura T, Kawana-Tachikawa A et al.: Comparison between Sendai virus and adenovirus vectors to transduce HIV-1 genes into human dendritic cells. J. Med. Virol. 80(3), 373-382 (2008).
106. Yu H, Babiuk LA, van Drunen LDHS: Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J. Viral Hepat. 15(6), 459-470 (2008).
107. Zabaleta A, Llopiz D, Arribillaga L et al.: Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol. Ther. 16(1), 210-217 (2008).
108. Van Gulck ER, Ponsaerts P, Heyndrickx L et al.: Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 107(5), 1818-1827 (2006).
109. Huang Y, Chen Z, Jia H et al.: Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg. Clin. Immunol. 119(3), 280-290 (2006).
110. Wang Q, Liu Y, Wang J et al.: Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J. Immunol. 177(4), 2175-2185 (2006).
111. Zhang M, Wang Q, Liu Y et al.: Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J. Mol. Med. 82(4), 240-249 (2004).
112. Min WP, Gorczynski R, Huang XY et al.: Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164(1), 161-167 (2000).
113. O'Rourke RW, Kang SM, Lower JA et al.: A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival. Transplantation 69(7), 1440-1446 (2000).
114. Takayama T, Kaneko K, Morelli AE et al.: Retroviral delivery of transforming growth factor-β1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74(1), 112-119 (2002).
115. Tiao MM, Lu L, Tao R et al.: Application of recipient-derived dendritic cells to induce donor-specific T-cell hyporesponsiveness. Transplant. Proc. 36(5), 1592-1594 (2004).
116. Fry JW, Morris PJ, Wood KJ: Adenoviral transfer of a single donor-specific MHC class I gene to recipient bone marrow cells can induce specific immunological unresponsiveness in vivo. Gene Ther. 9(3), 220-226 (2002).
117. Creusot RJ, Yaghoubi SS, Kodama K et al.: Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin. Immunol. 127(2), 176-187 (2008).
118. Perone MJ, Bertera S, Tawadrous ZS et al.: Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J. Immunol. 177(8), 5278-5289 (2006).
119. Lai KLQ, King HKO, Zheng BJ et al.: Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl Acad. Sci. USA, 105(39), 14993-14998 (2008).
120. Hirata S, Senju S, Matsuyoshi H et al.: Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J. Immunol. 174(4), 1888-1897 (2005).
121. Mahnke K, Qian Y, Knop J et al.: Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat. Biotechnol. 21(8), 903-908 (2003).
122. Ohmura-Hoshino M, Matsuki Y, Aoki M et al.: Inhibition of MHC class II expression and immune responses by c-MIR. J. Immunol. 177(1), 341-354 (2006).
123. Kim SH, Bianco NR, Shufesky WJ et al.: Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 179(4), 2242-2249 (2007).